TrialBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2018

Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.

Yago Nieto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.